The efficacy of cyclospolin A and low dose mycophenolate mofetil to prevent GVHD for reduced-intensity (fludarabine , cyclophosphamide , total body irradiation) cord blood stem cell transplantatio
Not Applicable
- Conditions
- Hematologic malignancies
- Registration Number
- JPRN-UMIN000001758
- Lead Sponsor
- RICBT Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 57
Inclusion Criteria
Not provided
Exclusion Criteria
1) Double cancer 2) Sever mental disease 3)Seropositive to HIV 4) History of adverse reaction for the agents included in the protocol in conditioning (fludarabine, cyclophosphamide), in GVHD prophylaxis (Cyclosporine A, mycophenolate mofetil) 5) Pregnant or lactating women 6)Inadequate to entry judged by investigators.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method on relapse mortality on day 100 post transplantaion
- Secondary Outcome Measures
Name Time Method 1)Incidence and severity of acute GVHD 2)Incidence of hepatic veno-occlusive disease and thrombotic microangiopathy 3)Incidence of infectious disease 4)Disease-free survival and overall survival rate at 1 year and 2 years after transplantation 5)Engraftment rate 100 days after transplantation 6)Time to hematopoietic recovery